RJFSA
HRTX icon

Raymond James Financial Services Advisors’s Heron Therapeutics HRTX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$111K Buy
55,595
+21,769
+64% +$52K ﹤0.01% 3281
2024
Q2 		$118K Sell
33,826
-23,140
-41% -$71.1K ﹤0.01% 3206
2024
Q1 		$158K Buy
56,966
+8,657
+18% +$21.8K ﹤0.01% 3153
2023
Q4 		$82.1K Buy
48,309
+18,333
+61% +$20.2K ﹤0.01% 3149
2023
Q3 		$30.9K Sell
29,976
-2,974
-9% -$4.23K ﹤0.01% 3172
2023
Q2 		$38.2K Buy
+32,950
New +$58.8K ﹤0.01% 3147
2023
Q1 		– Sell
-12,025
Closed -$30.1K – 3330
2022
Q4 		$30.1K Sell
12,025
-85
-0.7% -$274 ﹤0.01% 3129
2022
Q3 		$51K Buy
12,110
+324
+3% +$1.27K ﹤0.01% 3089
2022
Q2 		$33K Sell
11,786
-25
-0.2% -$100 ﹤0.01% 3122
2022
Q1 		$68K Buy
11,811
+950
+9% +$6.95K ﹤0.01% 3158
2021
Q4 		$99K Sell
10,861
-395
-4% -$4.03K ﹤0.01% 3124
2021
Q3 		$120K Sell
11,256
-265
-2% -$3.23K ﹤0.01% 3092
2021
Q2 		$179K Sell
11,521
-7,550
-40% -$120K ﹤0.01% 3041
2021
Q1 		$309K Buy
19,071
+1,876
+11% +$33.4K ﹤0.01% 2606
2020
Q4 		$364K Buy
17,195
+775
+5% +$13.5K ﹤0.01% 2337
2020
Q3 		$243K Sell
16,420
-5,678
-26% -$88.6K ﹤0.01% 2411
2020
Q2 		$325K Buy
+22,098
New +$363K ﹤0.01% 2184

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial Services Advisors's HRTX Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Heron Therapeutics (HRTX) stake by 64% in Q3 2024, buying an estimated $52K and bringing the position to 55,595 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #3281.

Raymond James Financial Services Advisors first reported a position in HRTX in Q2 2020 and has held it in 17 quarters since. The position peaked at $364K in Q4 2020. 173 funds tracked by Wall St. Rank hold HRTX as of Q3 2024.

  • Raymond James Financial Services Advisors held 55,595 shares of Heron Therapeutics worth $111K as of Q3 2024.
  • Raymond James Financial Services Advisors bought 21,769 Heron Therapeutics shares in Q3 2024, an estimated $52K.
  • Heron Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3281 holding.
  • Raymond James Financial Services Advisors first reported a position in Heron Therapeutics in Q2 2020 and has held it in 17 quarters since.
  • Raymond James Financial Services Advisors's Heron Therapeutics position peaked at $364K in Q4 2020.
  • 173 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.